Avadel Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Avadel Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -32.2%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 0.1%. De inkomsten zijn daalde met een gemiddeld percentage van 20.7% per jaar.

Belangrijke informatie

-32.2%

Groei van de winst

-16.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	-20.7%
Rendement op eigen vermogen	-151.1%
Nettomarge	-111.6%
Volgende winstupdate	12 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11

Opbrengsten en kosten

Hoe Avadel Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:AVDL Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	95	-106	176	12
31 Mar 24	55	-157	176	12
31 Dec 23	28	-160	152	13
30 Sep 23	9	-159	127	17
30 Jun 23	1	-143	102	17
31 Mar 23	0	-142	77	18
31 Dec 22	0	-137	75	21
30 Sep 22	0	-132	79	17
30 Jun 22	0	-134	86	18
31 Mar 22	0	-90	79	20
31 Dec 21	0	-77	68	17
30 Sep 21	0	-66	56	20
30 Jun 21	0	-56	44	21
31 Mar 21	10	-6	36	19
31 Dec 20	22	7	32	20
30 Sep 20	33	16	31	23
30 Jun 20	48	18	28	25
31 Mar 20	55	-21	28	31
31 Dec 19	59	-33	30	33
30 Sep 19	69	-94	46	31
30 Jun 19	75	-101	65	35
31 Mar 19	86	-96	86	37
31 Dec 18	103	-95	100	39
30 Sep 18	117	-40	101	66
30 Jun 18	137	-2	88	54
31 Mar 18	154	30	73	42
31 Dec 17	173	68	59	33
30 Sep 17	182	81	46	0
30 Jun 17	174	40	48	0
31 Mar 17	167	-9	47	0
31 Dec 16	150	-41	45	34
30 Sep 16	152	28	40	0
30 Jun 16	167	19	32	0
31 Mar 16	177	23	27	0
31 Dec 15	173	42	22	0
30 Sep 15	127	-64	19	0
30 Jun 15	87	-46	18	0
31 Mar 15	43	-49	17	0
31 Dec 14	15	-89	16	0
30 Sep 14	4	-56	17	0
30 Jun 14	2	-52	16	0
31 Mar 14	4	-65	14	0
31 Dec 13	4	-47	13	0

Kwaliteitswinsten: AVDL is momenteel verliesgevend.

Groeiende winstmarge: AVDL is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: AVDL is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 32.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van AVDL over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: AVDL is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 36.7% ).

Rendement op eigen vermogen

Hoge ROE: AVDL heeft een negatief Return on Equity ( -151.13% ), omdat het momenteel verliesgevend is.

Avadel Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Avadel Pharmaceuticals plc to Report Q1, 2022 Results on May 09, 2022

Recent updates

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals plc Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals: Inflection Point Ahead

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension (CIII) Data at Sleep 2024

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals plc has completed a Follow-on Equity Offering.

Avadel Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Price target increased by 9.8% to US$18.06

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Independent Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 17%

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Price target increased by 20% to US$15.85

Consensus revenue estimates fall by 15%

Consensus revenue estimates increase by 15%, EPS downgraded

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Price target increased to US$12.25

Independent Director recently bought US$156k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Price target increased to US$10.95

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Price target increased to US$10.10

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel Pharmaceuticals Provides Corporate Update

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Senior VP & CFO recently bought US$107k worth of stock

Price target decreased to US$11.30

Consensus revenue estimates fall by 15%

Avadel Pharmaceuticals plc to Report Q1, 2022 Results on May 09, 2022

Avadel Pharmaceuticals plc, Annual General Meeting, Aug 04, 2022

Consensus revenue estimates fall by 16%